Titre
Absence of hepatitis delta infection in a large rural HIV cohort in Tanzania.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Winter, A.
Auteure/Auteur
Letang, E.
Auteure/Auteur
Vedastus Kalinjuma, A.
Auteure/Auteur
Kimera, N.
Auteure/Auteur
Ntamatungiro, A.
Auteure/Auteur
Glass, T.
Auteure/Auteur
Moradpour, D.
Auteure/Auteur
Sahli, R.
Auteure/Auteur
Le Gal, F.
Auteure/Auteur
Furrer, H.
Auteure/Auteur
Wandeler, G.
Auteure/Auteur
Groupes de travail
KIULARCO Study Group
Liens vers les personnes
Liens vers les unités
ISSN
1878-3511
Statut éditorial
Publié
Date de publication
2016-03
Volume
46
Première page
8
Dernière page/numéro d’article
10
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
The epidemiological and clinical determinants of hepatitis delta virus (HDV) infection in Sub-Saharan Africa are ill-defined. The prevalence of HDV infection was determined in HIV/hepatitis B virus (HBV) co-infected individuals in rural Tanzania.
All HBV-infected adults under active follow-up in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) were screened for anti-HDV antibodies. For positive samples, a second serological test and nucleic acid amplification were performed. Demographic and clinical characteristics at initiation of antiretroviral therapy (ART) were compared between anti-HDV-negative and -positive patients.
Among 222 HIV/HBV co-infected patients on ART, 219 (98.6%) had a stored serum sample available and were included in the study. Median age was 37 years, 55% were female, 46% had World Health Organization stage III/IV HIV disease, and the median CD4 count was 179 cells/μl. The prevalence of anti-HDV positivity was 5.0% (95% confidence interval 2.8-8.9%). There was no significant predictor of anti-HDV positivity. HDV could not be amplified in any of the anti-HDV-positive patients and the second serological test was negative in all of them.
No confirmed case of HDV infection was found among over 200 HIV/HBV co-infected patients in Tanzania. As false-positive serology results are common, screening results should be confirmed with a second test.
All HBV-infected adults under active follow-up in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) were screened for anti-HDV antibodies. For positive samples, a second serological test and nucleic acid amplification were performed. Demographic and clinical characteristics at initiation of antiretroviral therapy (ART) were compared between anti-HDV-negative and -positive patients.
Among 222 HIV/HBV co-infected patients on ART, 219 (98.6%) had a stored serum sample available and were included in the study. Median age was 37 years, 55% were female, 46% had World Health Organization stage III/IV HIV disease, and the median CD4 count was 179 cells/μl. The prevalence of anti-HDV positivity was 5.0% (95% confidence interval 2.8-8.9%). There was no significant predictor of anti-HDV positivity. HDV could not be amplified in any of the anti-HDV-positive patients and the second serological test was negative in all of them.
No confirmed case of HDV infection was found among over 200 HIV/HBV co-infected patients in Tanzania. As false-positive serology results are common, screening results should be confirmed with a second test.
Sujets
PID Serval
serval:BIB_6F39DB50F07D
PMID
Open Access
Oui
Date de création
2016-02-16T16:50:54.975Z
Date de création dans IRIS
2025-05-21T03:07:04Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
BIB_6F39DB50F07D.P001.pdf
Version du manuscrit
preprint
Taille
266.94 KB
Format
Adobe PDF
PID Serval
serval:BIB_6F39DB50F07D.P001
URN
urn:nbn:ch:serval-BIB_6F39DB50F07D7
Somme de contrôle
(MD5):2adc0eea10f940a278ccc4d716c75dff